Science
Mechanism of Action
The general mechanism of bacteriophage T4 involves lysing specific bacterial hosts, such as *Escherichia coli*, by replicating within the bacterial cell and causing it to burst. This lytic action, often mediated by enzymes like T4 lysozyme, targets bacterial cell walls. For S-ENTEROBACTERIA PHAGE T4 DECAPEPTIDE-1 SP TRIFLUOROACETATE, the 'decapeptide' likely represents a specialized sequence intended to specifically interact with bacterial components or modulate skin cellular responses, though its exact mechanism of action as an isolated peptide on the skin is not explicitly detailed in the available literature.
Research
Clinical Evidence
Low confidenceN/A
Key findings
- 01 Studies on the full T4 bacteriophage indicate effective concentrations for bacterial reduction in general applications are around 10^8 PFU/mL. Oral administration of T4 phage at 10^3 PFU/ml and 10^5 PFU/ml has been well tolerated in human volunteers without significant adverse events.
- 02 T4-like bacteriophages have demonstrated *in vitro* efficacy, reducing *E. coli* O45:H16 by 5 log at a Multiplicity of Infection (MOI) of 10, and by 2 log on contaminated mung bean seeds at an MOI of 1,000.
Transparency
Dusting Analysis
No data available to suggest common dusting practices or specific thresholds for this ingredient.
The Formula
Formulation
Stability
Bacteriophage T4, from which this peptide is derived, demonstrates stability across a broad pH range of 3.0 to 10.5, with optimal infectivity maintained between pH 5 and 11. Significant activity is observed at pH 7 and 8, compared to pH 6. It also exhibits good antibacterial activity and recovery between 31°C and 40°C, particularly at pH 7 and 38°C. Material adsorption, such as on paper, can further enhance stability against pH fluctuations. However, engineered phage components may be susceptible to inactivation by the complement system in biological environments.
Safety
Safety Profile
The ingredient has not undergone specific review by CIR or SCCS for cosmetic applications. While the FDA sets a limit of <5 endotoxin units/kg body weight/h for broader therapeutic phage formulations, no specific maximum concentration for cosmetic use of this decapeptide is established. Safety studies on oral T4 *E. coli* phage in human volunteers reported no significant adverse events and good tolerability, with no detection of T4 phage or specific antibodies in serum. However, this data refers to the whole phage, not the isolated decapeptide.
Your Skin
Skin Compatibility
Our Assessment
Verdict
While conceptually promising as a phage-inspired peptide for microbiome modulation, there is insufficient specific clinical and safety data on S-ENTEROBACTERIA PHAGE T4 DECAPEPTIDE-1 SP TRIFLUOROACETATE itself for topical cosmetic application, with most available research pertaining to the full T4 bacteriophage.
Related
Similar Ingredients
Finding similar ingredients…